Follow on Google News News By Tag * Top 10 * Contract Research * Research Organizations * Swot Analyses Research * Market Research Reports * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | The Top 10 Contract Research Organizations now available at ReportsandReports‘The Top 10 Contract Research Organizations’ is a report published by Business Insights that examines the competitive landscape of the global CRO industry.
By: ReportsandReports Report Description: The Top 10 Contract Research Organizations: Cost containment and regulatory pressures within the pharma industry are driving R&D outsourcing across the globe. Clinical obstacles to approval have become more significant due to the growing availability of existing generic treatments, and the trend to adopt Health Economics Outcomes Research (HEOR) assessments is increasing the complexity of clinical research. As a result, the scope of the CRO industry is expanding, and the global market is predicted to value $35bn by 2013. ‘The Top 10 Contract Research Organizations’ Table of Contents Chapter 1 Introduction 22 • What is this report about? 22 • Methodology 22 Chapter 2 Industry overview 24 • Summary 24 • Introduction 25 • Market overview 25 • Global CRO market: size and growth 25 • Global positioning of the top 10 CROs 26 • Key market drivers 29 • Key market resistors 30 • Business models 31 • Full-services CROs 31 • Niche CROs 31 • Trends in the global CRO industry 32 • Consolidation in the CRO industry 32 • Evolution of software as a service (SaaS) based electronic data capture (EDC) 35 • Implementation of biomarkers in clinical trials 36 • Participation of private equity players 38 • New CRO destinations 39 • Asia-Pacific 39 • India 39 • China 40 • Latin America 42 • Eastern Europe 42 • Africa 43 Chapter 3 Quintiles 46 • Summary 46 • Company overview 47 • Recent financial performance 48 • Growth strategies 48 • Investing in infrastructure 48 • Expansion of consulting business 50 • Acquisitions and divestments 50 • SWOT analysis 51 • Strengths 52 • Depth in service offerings 52 • Strong presence in emerging economies 52 • Weaknesses 53 • Exposure in limited therapeutic areas 53 • Opportunities 53 • Launch of interactive data analysis tool 53 • New facility in India 53 • Expansion in Japan 53 • Threats 54 • Stringent regulations 54 • Increasing competition 55 Chapter 4 Covance 58 • Summary 58 • Company overview 59 • Recent financial performance 59 • Performance by business segment 61 • Growth strategies 61 • Attaining operational efficiency through six sigma implementation 61 • Develop capabilities in emerging markets 62 • Acquisitions and divestments 62 • SWOT analysis 63 • Strengths 63 • Global capabilities 63 • Stronger therapeutic base 64 • Strong liquidity position 64 • Weaknesses 64 • Declining performance in late-stage segment 64 • Opportunities 65 • Expanding facilities in mature pharmaceutical markets 65 • R&D collaboration with Eli Lilly 65 • Threats 66 • Weakening early-stage development segment 66 • Regulatory compliance 66 Chapter 5 Pharmaceutical Product Development 68 • Summary 68 • Company overview 69 • Recent financial performance 69 • Performance by business segment 70 • Growth strategies 71 • Collaboration for development of innovative compounds 71 • Expansion in central laboratory services 71 • Acquisitions and divestments 72 • SWOT analysis 73 • Strengths 74 • Depth in phase II–IV service offering 74 • Strong financial performance 74 • Weaknesses 74 • Declining revenue contribution from PPD’s discovery segment 74 • Opportunities 75 • Investment in technologies 75 • Geographical expansion 75 • Outsourcing deal with Merck 76 • Threats 76 • Dependence on a small number of industries and clients 76 Chapter 6 Charles River Laboratories 78 • Summary 78 • Company overview 79 • Recent financial performance 79 • Performance by business segment 80 • Growth strategies 81 • Building capabilities for clients 81 • Acquisitions and divestments 81 • SWOT analysis 82 • Strengths 83 • Strong technology platforms for pre-clinical testing 83 • Weaknesses 83 • Higher debt burden 83 • Opportunities 84 • Expansion in China 84 • Threats 84 • Cost cutting in biopharmaceutical industry 84 Chapter 7 ICON 86 • Summary 86 • Company overview 87 • Recent financial performance 87 • Performance by business segments 88 • Growth strategies 88 • Developing global capabilities and reach 88 • Acquisitions and divestments 89 • SWOT analysis 90 • Strengths 90 • Strong presence in oncology solutions 90 • Technically enhanced service offerings 91 • Unconventional service model 91 • Weaknesses 92 • Rising debt load 92 • Opportunities 92 • Expansion in India 92 • Agreement with Phase Forward 92 • Threats 93 • Government regulations 93 • Softness in non-Critical Path studies 93 Chapter 8 Parexel 96 • Summary 96 • Company overview 97 • Recent financial performance 97 • Performance by business segments 98 • Growth strategies 99 • Expansion in emerging markets 99 • Acquisitions and divestments 100 • SWOT analysis 101 • Strengths 101 • Strong global presence 101 • Stronger therapeutic presence 102 • Weaknesses 102 • Increased receivable turnover period 102 • Opportunities 102 • Expansion in early-phase service offerings 102 • Threats 103 • Consolidation in the industry 103 • Declining R&D spending growth 103 Chapter 9 MDS 106 • Summary 106 • Company overview 107 • Recent financial performance 107 • Performance by business segment 109 • Growth strategies 109 • Internal restructuring 109 • Investment in infrastructure across geographies 110 • Acquisitions and divestments 110 • SWOT analysis 111 • Strengths 111 • Robust performance of late-stage contract research services 111 • Weaknesses 112 • Limited therapeutic focus 112 • Opportunities 112 • Investment in technology 112 • Expansion in Asian markets 113 • Threats 113 • Regulatory review 113 Chapter 10 Kendle 116 • Summary 116 • Company overview 117 • Recent financial performance 117 • Performance by business segment 119 • Growth strategies 119 • Participation in mega-trials 119 • Acquisitions and divestments 120 • SWOT analysis 121 • Strengths 121 • Strong presence in phase I–IV clinical services 121 • Growth in operating profit 122 • Broader therapeutic exposure 122 • Weaknesses 123 • Rising debt burden 123 • Opportunities 123 • Growth in the early-stage research segment 123 • Expansion in Asia-Pacific 124 • Threats 124 • Highly competitive environment 124 Browse complete Report at: http://www.reportsandreports.com/ About Us: Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers. Contact: Ms. Sunita 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004 Website: http://www.reportsandreports.com/ Blog: http://reportsnreports.wordpress.com/ Blog: http://reportsandreports.blogspot.com/ # # # Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. End
Page Updated Last on: Sep 14, 2010
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
